Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 1
2016 1
2020 1
2022 1
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

6 results

Results by year

Filters applied: . Clear all
Page 1
Systemic Therapy for Melanoma: ASCO Guideline Update.
Seth R, Agarwala SS, Messersmith H, Alluri KC, Ascierto PA, Atkins MB, Bollin K, Chacon M, Davis N, Faries MB, Funchain P, Gold JS, Guild S, Gyorki DE, Kaur V, Khushalani NI, Kirkwood JM, McQuade JL, Meyers MO, Provenzano A, Robert C, Santinami M, Sehdev A, Sondak VK, Spurrier G, Swami U, Truong TG, Tsai KK, van Akkooi A, Weber J. Seth R, et al. J Clin Oncol. 2023 Oct 20;41(30):4794-4820. doi: 10.1200/JCO.23.01136. Epub 2023 Aug 14. J Clin Oncol. 2023. PMID: 37579248
UPDATED RECOMMENDATIONS: Neoadjuvant pembrolizumab was newly recommended for patients with resectable stage IIIB to IV cutaneous melanoma. For patients with resected cutaneous melanoma, adjuvant nivolumab or pembrolizumab was newly recommended for stage IIB-C diseas …
UPDATED RECOMMENDATIONS: Neoadjuvant pembrolizumab was newly recommended for patients with resectable stage IIIB to IV cutaneous mela …
Systemic Therapy for Melanoma: ASCO Guideline.
Seth R, Messersmith H, Kaur V, Kirkwood JM, Kudchadkar R, McQuade JL, Provenzano A, Swami U, Weber J, Alluri KC, Agarwala S, Ascierto PA, Atkins MB, Davis N, Ernstoff MS, Faries MB, Gold JS, Guild S, Gyorki DE, Khushalani NI, Meyers MO, Robert C, Santinami M, Sehdev A, Sondak VK, Spurrier G, Tsai KK, van Akkooi A, Funchain P. Seth R, et al. J Clin Oncol. 2020 Nov 20;38(33):3947-3970. doi: 10.1200/JCO.20.00198. Epub 2020 Mar 31. J Clin Oncol. 2020. PMID: 32228358
RECOMMENDATIONS: In the adjuvant setting, nivolumab or pembrolizumab should be offered to patients with resected stage IIIA/B/C/D BRAF wild-type cutaneous melanoma, while either of those two agents or the combination of dabrafenib and trametinib should be offered in BRAF-m …
RECOMMENDATIONS: In the adjuvant setting, nivolumab or pembrolizumab should be offered to patients with resected stage IIIA/B/C/D BRA …
The Application of Artificial Intelligence in the Analysis of Biomarkers for Diagnosis and Management of Uveitis and Uveal Melanoma: A Systematic Review.
Bassi A, Krance SH, Pucchio A, Pur DR, Miranda RN, Felfeli T. Bassi A, et al. Clin Ophthalmol. 2022 Aug 30;16:2895-2908. doi: 10.2147/OPTH.S377358. eCollection 2022. Clin Ophthalmol. 2022. PMID: 36065357 Free PMC article. Review.
RESULTS: After screening 10,258 studies,18 studies met the inclusion criteria. Uveal melanoma (44%) and uveitis (56%) were the two uveal diseases examined. ...Lactate dehydrogenase (LDH), found in 50% of studies concerning uveal melanoma, was the only …
RESULTS: After screening 10,258 studies,18 studies met the inclusion criteria. Uveal melanoma (44%) and uveitis (56%) were the …
Is tebentafusp superior to combined immune checkpoint blockade and other systemic treatments in metastatic uveal melanoma? A comparative efficacy analysis with population adjustment.
Petzold A, Steeb T, Wessely A, Koch EAT, Vera J, Berking C, Heppt MV. Petzold A, et al. Cancer Treat Rev. 2023 Apr;115:102543. doi: 10.1016/j.ctrv.2023.102543. Epub 2023 Mar 13. Cancer Treat Rev. 2023. PMID: 36931146
BACKGROUND: Distinct systemic treatments exist for metastatic uveal melanoma. Tebentafusp and combined immune checkpoint blockade (ICB) with ipilimumab plus anti-PD-1 antibodies are the most commonly used treatment options but their comparative efficacy is unclear. …
BACKGROUND: Distinct systemic treatments exist for metastatic uveal melanoma. Tebentafusp and combined immune checkpoint block …
A systematic review of the cost and cost-effectiveness studies of proton radiotherapy.
Verma V, Mishra MV, Mehta MP. Verma V, et al. Cancer. 2016 May 15;122(10):1483-501. doi: 10.1002/cncr.29882. Epub 2016 Feb 1. Cancer. 2016. PMID: 26828647 Free article. Review.
Similar cost-effectiveness was observed for PBT, enucleation, and plaque brachytherapy in patients with uveal melanoma. CONCLUSIONS: With greatly limited amounts of data, PBT offers promising cost-effectiveness for pediatric brain tumors, well-selected breast cancer …
Similar cost-effectiveness was observed for PBT, enucleation, and plaque brachytherapy in patients with uveal melanoma. CONCLU …
Secondary glaucoma as initial manifestation of ring melanoma: a case report and review of literature.
Zhao M, Mu Y, Dang Y, Zhu Y. Zhao M, et al. Int J Clin Exp Pathol. 2014 Oct 15;7(11):8163-9. eCollection 2014. Int J Clin Exp Pathol. 2014. PMID: 25550867 Free PMC article. Review.
While the incidence rate of these tumors is low, malignant melanomas metastasize at early stages of disease development and show poor prognoses. Malignant melanomas of the ciliary body are often deeply hidden and have complex clinical manifestations, which are easily misdi …
While the incidence rate of these tumors is low, malignant melanomas metastasize at early stages of disease development and show poor …